AGL 40.00 Decreased By ▼ -0.16 (-0.4%)
AIRLINK 129.53 Decreased By ▼ -2.20 (-1.67%)
BOP 6.68 Decreased By ▼ -0.01 (-0.15%)
CNERGY 4.63 Increased By ▲ 0.16 (3.58%)
DCL 8.94 Increased By ▲ 0.12 (1.36%)
DFML 41.69 Increased By ▲ 1.08 (2.66%)
DGKC 83.77 Decreased By ▼ -0.31 (-0.37%)
FCCL 32.77 Increased By ▲ 0.43 (1.33%)
FFBL 75.47 Increased By ▲ 6.86 (10%)
FFL 11.47 Increased By ▲ 0.12 (1.06%)
HUBC 110.55 Decreased By ▼ -1.21 (-1.08%)
HUMNL 14.56 Increased By ▲ 0.25 (1.75%)
KEL 5.39 Increased By ▲ 0.17 (3.26%)
KOSM 8.40 Decreased By ▼ -0.58 (-6.46%)
MLCF 39.79 Increased By ▲ 0.36 (0.91%)
NBP 60.29 No Change ▼ 0.00 (0%)
OGDC 199.66 Increased By ▲ 4.72 (2.42%)
PAEL 26.65 Decreased By ▼ -0.04 (-0.15%)
PIBTL 7.66 Increased By ▲ 0.18 (2.41%)
PPL 157.92 Increased By ▲ 2.15 (1.38%)
PRL 26.73 Increased By ▲ 0.05 (0.19%)
PTC 18.46 Increased By ▲ 0.16 (0.87%)
SEARL 82.44 Decreased By ▼ -0.58 (-0.7%)
TELE 8.31 Increased By ▲ 0.08 (0.97%)
TOMCL 34.51 Decreased By ▼ -0.04 (-0.12%)
TPLP 9.06 Increased By ▲ 0.25 (2.84%)
TREET 17.47 Increased By ▲ 0.77 (4.61%)
TRG 61.32 Decreased By ▼ -1.13 (-1.81%)
UNITY 27.43 Decreased By ▼ -0.01 (-0.04%)
WTL 1.38 Increased By ▲ 0.10 (7.81%)
BR100 10,407 Increased By 220 (2.16%)
BR30 31,713 Increased By 377.1 (1.2%)
KSE100 97,328 Increased By 1781.9 (1.86%)
KSE30 30,192 Increased By 614.4 (2.08%)

Pakistani pharmaceutical company Abbott Laboratories suffered losses to the tune of Rs579.85 million in the second quarter which ended June, 30, 2023, as compared to a profit of Rs338.2 million in same period last year (SPLY).

The company, in its financial statements provided to the Pakistan Stock Exchange (PSX) on Wednesday, attributed the losses to a rise in production cost amid ongoing rupee devaluation and rise in inflation.

The company posted a loss per share of Rs5.93 in Q2 2023, as compared to an earning per share of Rs3.45 per share in SPLY.

Sales for the quarter clocked in at Rs13.44 billion, an increase of 4% over the SPLY.

“Pharmaceutical sales increased by 12% whereas sales for nutrition decreased by 18% mainly on account of lower volumes following restrained demand due to inflationary pressures,” said Abbott.

However, despite higher sales the pharmaceutical’s gross profit margin declined to 19% in 2QCY23 from 34% during the SPLY.

“This is mainly due to increase in product costs on account of rupee devaluation and inflation,” stated the company, as the cost of sales increased to Rs10.84 billion from Rs8.53 billion in SPLY.

Operating expenses increased by 16% over the same period last year mainly due to inflation. Other charges decreased by 82% over the same period last year due to impact of exchange losses in 2QCY22.

Abbott’s tax charge for the quarter decreased by 44% to Rs971.72 million as compared to 1.729 billion in SPLY. “This is in line with lower profitability and impact of prior year super tax levy in 2QCY22,” said the pharmaceutical.

Abbott stated it continues to face challenges of inflation and rupee devaluation.

It urged the Drug Regulatory Authority of Pakistan to conduct necessary pricing review and adjustments.

“As a long-term measure, the Authority may consider introducing automatic mechanism and policy to offset the impact of devaluation,” it suggested.

Comments

Comments are closed.

Tulukan Mairandi Aug 30, 2023 04:03pm
Time to shut shop and sell to Xibott of china
thumb_up Recommended (0)
TheActualTruth Aug 30, 2023 09:26pm
No Comments
thumb_up Recommended (0)
Saleem Munshi Aug 31, 2023 01:20pm
And the show must go on at whatever cost it may be to all except the puppet masters.
thumb_up Recommended (0)